Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemprocitinib in active ankylosing spondylitis
NCT07237568Phase 3Recruiting
- Sponsor
- Lynk Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zemprocitinib in ankylosing spondylitis (AS), sponsored by Lynk Pharmaceuticals. Started Aug 2025; status: recruiting.
02
Drugs
zemprocitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07237568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237568.